Celgene launches patient support program for myeloma
Support Coordinators are oncology nurses and other trained professionals available by phone to help patients work their way through the complexities of drug access and reimbursement.
Celgene has established a new Patient Support Coordinator program for myeloma patients. Myeloma, also called multiple myeloma, is a cancer of the bone marrow that affects the production of red cells, white cells, and stem cells. Patient Support Coordinators are oncology nurses and other trained professionals available by phone to help patients work their way through the complexities of drug access and reimbursement. The program was applauded by the International Myeloma Foundation (IMF), which raised patient concerns about access to cancer drugs, reimbursement by Medicare and private insurance, co-pay assistance from foundations, and free access to drugs for the uninsured. The program was recently unveiled at IMF's meeting in Phoenix. IMF is the oldest and largest myeloma organization.
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
Targeted Drug Combination Reveals New Activity in Brain Tumors
December 28th 2021A combination of two targeted cancer drugs showed unprecedented, “clinically meaningful” activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.
